EFFECTS OF ANTIARRHYTHMIC DRUGS ON CANINE VENTRICULAR ARRHYTHMIA MODELS - WHICH ELECTROPHYSIOLOGICAL CHARACTERISTICS OF DRUGS ARE RELATED TO THEIR EFFECTIVENESS

被引：56

作者：

HASHIMOTO, K

HARUNO, A

MATSUZAKI, T

SUGIYAMA, A

AKIYAMA, K

机构：

[1] Department of Pharmacology, Yamanashi Medical College, Yamanashi

[2] Department of Pharmacology, Yamanashi Medical College, Yamanashi, 409-38, Tamaho-cho, Nakakoma-gun

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1991年 / 5卷

关键词：

ANTIARRHYTHMIC DRUGS; EFFECTIVE ANTIARRHYTHMIC PLASMA CONCENTRATION; VENTRICULAR ARRHYTHMIAS; TRIGGERED ARRHYTHMIAS;

D O I：

10.1007/BF00120829

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In order to compare and clarify the effects of various antiarrhythmic drugs when given as monotherapy, we reevaluated our previous data on antiarrhythmic drugs and recalculated antiarrhythmic plasma concentrations of drugs for several canine arrhythmia models. We used three spontaneously occurring arrhythmias: a) digitalis-, b) two-stage coronary ligation-, and c) adrenaline-induced arrhythmias. All antiarrhythmic drugs of class I suppressed digitalis arrhythmia, and, except for lidocaine, also suppressed coronary ligation arrhythmia. Class II antiarrhythmic drugs, beta blockers, and class IV antiarrhythmic drugs, Ca antagonists, had common features of effectiveness and suppressed adrenaline arrhythmia in relatively low concentrations. Class III drugs were not effective on these three arrhythmias. Differences among the antiarrhythmic effects of class I drugs could not be explained by their subclassification based either on action potential duration or kinetic properties of dissociation or association with Na channels. New triggered arrhythmia models in vivo and in vitro canine hearts were developed, and drug effects were not the same as those on the three spontaneously occurring arrhythmia models.

引用

页码：805 / 818

页数：14

共 40 条

[1]

Hashimoto K., Tsukada T., Matsuda H., Et al., Antiarrhythmic effect of oxprenolol on halothane-epinephrine and coronary ligation induced ventricular arrhythmias in beagle dogs, Jpn J Pharmacol, 28, pp. 535-544, (1978)

[2]

Hashimoto K., Tsukada T., Matsuda H., Et al., Antiarrhythmic effects of bupranolol against canine ventricular arrhythmias induced by halothane-adrenaline or two stage coronary ligation, J Cardiovasc Pharmacol, 1, pp. 205-217, (1979)

[3]

Hashimoto K., Satoh H., Shibuya T., Imai S., Canine-effective plasma concentrations of antiarrhythmic drugs on the twostage coronary ligation arrhythmia, J Pharmacol Exp Ther, 223, pp. 801-810, (1982)

[4]

Hashimoto K., Shibuya T., Satoh H., Imai S., Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations, Jpn Circ J, 47, pp. 92-97, (1983)

[5]

Shibuya T., Hashimoto K., Imai S., Effective plasma concentrations of antiarrhythmic drugs against sustained halothane-adrenaline arrhythmia in dogs, J Cardiovasc Pharmacol, 5, pp. 538-545, (1983)

[6]

Hashimoto K., Komori S., Ishii M., Kamiya J., Effective plasma concentrations of aprindine in canine ventricular arrhythmias, J Cardiovasc Pharmacol, 6, pp. 12-19, (1984)

[7]

Hashimoto K., Ishii M., Komori S., Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias, J Cardiovasc Pharmacol, 6, pp. 213-219, (1984)

[8]

Ishii M., Komori S., Satoh H., Et al., Effects of N-696, a new β-blocking agent, on canine experimental arrhythmias, Folia Pharmacol Japon, 84, pp. 259-266, (1984)

[9]

Komori S., Ishii M., Hashimoto K., Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models, Coronary, 1, pp. 397-404, (1984)

[10]

Hashimoto K., Ishii M., Komori S., Mitsuhashi H., Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: A comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165, Heart Vessels, 1, pp. 29-35, (1985)

← 1 2 3 4 →